Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/334223
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Antibody isotype epitope mapping of SARS-CoV-2 Spike RBD protein: Targets for COVID-19 symptomatology and disease control |
Autor: | Contreras, Marinela CSIC ORCID ; Vicente, Joaquín CSIC ORCID ; Cerón, José J.; Martínez-Subiela, Silvia; Urra, José Miguel; Rodríguez del‐Río, Francisco J.; Ferreras-Colino, Elisa CSIC ORCID; Vaz Rodrigues, Rita CSIC ORCID; Fernández de Mera, Isabel G. CSIC ORCID; Antunes, Sandra; Domingos, Ana; Gortázar, Christian CSIC ORCID ; Fuente, José de la CSIC ORCID | Fecha de publicación: | 2023 | Editor: | Wiley-VCH | Citación: | European Journal of Immunology 53(4): 2250206 (2023) | Resumen: | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still poses a challenge for biomedicine and public health. To advance the development of effective diagnostic, prognostic, and preventive interventions, our study focused on high-throughput antibody binding epitope mapping of the SARS-CoV-2 spike RBD protein by IgA, IgM and IgG antibodies in saliva and sera of different cohorts from healthy uninfected individuals to SARS-CoV-2-infected unvaccinated and vaccinated asymptomatic, recovered, nonsevere, and severe patients. Identified candidate diagnostic (455-LFRKSNLKPFERD-467), prognostic (395-VYADSFVIRGDEV-407-C-KLH, 332-ITNLCPFGEV-342-C-KLH, 352-AWNRKRI-358-C-KLH, 524-VCGPKKSTNLVKN-536-KLH), and protective (MKLLE-487-NCYFPLQSYGFQPTNGVG-504-GGGGS-446-GGNYNYLYRLFRKSNLKPFERD-467) epitopes were validated with sera from prevaccine and postvaccine cohorts. The results identified neutralizing epitopes and support that antibody recognition of linear B-cell epitopes in RBD protein is associated with antibody isotype and disease symptomatology. The findings in asymptomatic individuals suggest a role for anti-RBD antibodies in the protective response against SARS-CoV-2. The possibility of translating results into diagnostic interventions for the early diagnosis of asymptomatic individuals and prognosis of disease severity provides new tools for COVID-19 surveillance and evaluation of risks in hospitalized patients. These results, together with other approaches, may contribute to the development of new vaccines for the control of COVID-19 and other coronavirus-related diseases using a quantum vaccinomics approach through the combination of protective epitopes. | Versión del editor: | https://doi.org/10.1002/eji.202250206 | URI: | http://hdl.handle.net/10261/334223 | DOI: | 10.1002/eji.202250206 | E-ISSN: | 1521-4141 |
Aparece en las colecciones: | (IREC) Artículos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
antibodycontrol.pdf | 5,27 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
2
checked on 24-abr-2024
WEB OF SCIENCETM
Citations
2
checked on 18-feb-2024
Page view(s)
42
checked on 30-abr-2024
Download(s)
20
checked on 30-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons